|
[1]World Health Organization Hepatitis B[DB/OL].World HealthOrganization Fact Sheet NO204 (Revised August 2008) .http://www.who.int/mediacentre/factsheets/fs204/enindex.html.
|
|
[2]Lu FM, Zhuang H.Management of hepatitis B in China[J].Chin Med J, 2009, 122 (1) :3-4.
|
|
[3]李兰娟.加强肝衰竭发病机制和人工肝治疗的研究[J].中华肝脏病杂志, 2009, 17 (5) :321-323.
|
|
[4] 刘晓燕, 胡瑾华, 王慧芬, 等.1977例急性、亚急性、慢加急性肝衰竭患者的病因与转归分[J].中华肝脏病杂志, 2008, 16 (10) :772-775.
|
|
[5]Zhang H, Wu LY, Zhang S, et al.Anti-hepatitis B virus Xprotein in sera is one of the markers of development of livercirrhosis and liver cancer mediated by HBV[J].J BiomedBiotechnol, 2009, 2009:289068.
|
|
[6]Xu Z, Ren X, Liu Y, et al.Association of hepatitis B virusmutations in basal core promoter and precore regions withseverity of liver disease:an investigation of 793 Chinese pa-tients with mild and severe chronic hepatitis B and acute-on-chronic liver failure[J].J Gastroenterol, 2011, 46 (3) :391-400.
|
|
[7]Ren X, Xu Z, Liu Y, et al.Hepatitis B virus genotype andbasal core promoter/precore mutations are associated withhepatitis B-related acute-on-chronic liver failure withoutpre-existing liver cirrhosis[J].J Viral Hepat, 2010, 17 (12) :887-895.
|
|
[8]Yang L, Ma S, Hu X, et al.Presence of valine at position 27of the hepatitis B virus core gene is associated with severeliver inflammation in Chinese patients[J].J Med Virol, 2011, 83 (2) :218-224.
|
|
[9]李兰娟, 王宇明.传染病学[M].北京:人民卫生出版社, 2008:65-79.
|
|
[10]叶一农, 高志良.乙型肝炎肝衰竭发生机制中的三重打击[J].传染病信息, 2009, 22 (5) :276-279.
|
|
[11]Tsubota A, Arase Y, Suzuki Y, et al.Lamivudine monothera-py for spontaneous severe acute exacerbation of chronic hep-atitis B[J].J Gastroenterol Hepatol, 2005, 20 (3) :426-432.
|
|
[12]Yu JW, Sun LJ, Zhao YH, et al.The study of efficacy oflamivudine in patients with severe acute hepatitis B[J].DigDis Sci, 2010, 55 (3) :775-783.
|
|
[13]Cui YL, Yan F, Wang YB, et al.Nucleoside analogue canimprove the long-term prognos is of patients with hepatitisB virus infection associated acute on chronic liver failure[J].Dig Dis Sci, 2010, 55 (8) :2373-2380.
|
|
[14]Tillmann HL, Hadem J, Leifeld L, et al.Safety and efficacyof lamivudine in patients with severe acute or Fulminant hep-atitis B, amulticenter experience[J].J Viral Hepat, 2006, 13 (4) :256-263.
|
|
[15]张南, 夏杰, 邓国宏, 等.拉米夫定对慢性重型乙型肝炎患者生存率的提高[J].第三军医大学学报, 2008, 30 (1) :75-77.
|
|
[16]Wong VW, Wong GL, Tsang SW, et al.Long-term follow-up of lamivudine treatment in patients with severe acuteexacerbation of hepatitis Be antigen (HBeAg) -positive chro-nic hepatitis B[J].Antivir Ther, 2008, 13 (4) :571-579.
|
|
[17]Schiff E, Lai CL, Hadziyannis S, et al.Adefovir dipivoxil forwaitlisted and post-liver transplantation patients with lami-vudine-resistant hepatitis B:final long-term results[J].Liver Transpl, 2007, 13 (3) :349-360.
|
|
[18]Lo CM, Liu CL, Lau GK, et al.Liver transplantation for chro-nic hepatitis B with Lamivudine-resistant YMDD mutant u-sing add-on adefovir dipivoxil plus lamivudine[J].LiverTranspl, 2005, 11 (7) :807-813.
|
|
[19]Hosaka T, Suzuki F, Suzuki Y, et al.Adefovir dipivoxil fortreatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus[J].Intervirology, 2004, 47 (6) :362-369.
|
|
[20]吴广利, 侯敏, 吴立强, 等.拉米夫定相关性慢加急性肝衰竭8例[J].肝脏, 2008, 13 (40) :355.
|
|
[21]舒欣, 徐启桓, 陈旎, 等.HBeAg阴性乙型肝炎ACLF患者的临床特征及抗病毒治疗短期疗效[J].中华实验和临床病毒学杂志, 2008, 22 (6) :481-483.
|
|
[22]舒欣, 徐启桓, 陈旎, 等.恩替卡韦在乙型肝炎慢加急性肝功能衰竭中的应用[J].中华传染病杂志, 2009, 27 (5) :281-286.
|
|
[23]胡瑾华, 黄坤, 王慧芬, 等.乙型肝炎相关慢加急性肝衰竭190例生存分析[J].传染病信息, 2010, 23 (2) :83-85.
|
|
[24]Chen T, He Y, Liu X, et al.Nucleoside analogues improvethe short-term and long-term prognosis of patients withhepatitis B virus-related acute-on-chronic liver failure[J].Clin Exp Med, 2011 Oct 15.[Epub ahead of print]
|
|
[25]李芳, 陶晨, 杜建霞.恩替卡韦治疗慢性乙型重型肝炎的近期疗效观察[J].实用肝脏病杂志, 2008, 11 (6) :383-384.
|
|
[26]Chen J, Han JH, Liu C, et al.Short-term entecavir thera-py of chronic severe hepatitis B[J].Hepatobiliary PancreatDis Int, 2009, 8 (3) :261-266.
|
|
[27]Wong VW, Wong GL, Yiu KK, et al.Entecavir treatment inpatients with severe acute exacerbation of chronic hepatitis B[J].J Hepatol, 2011, 54 (2) :236-242.
|
|
[28]郑玉山, 孙凤兰, 刘现红.替比夫定与恩替卡韦治疗慢加急性肝衰竭的疗效分析[J].临床肝胆病杂志, 2011, 27 (6) :641-642, 646.
|
|
[29]Heathcote EJ, Marcellin P, Buti M, et al.Three-year effi-cacy and safety of tenofovir disoproxil fumarate treatment forchronic hepatitis B[J].Gastroenterology, 2011, 140 (1) :132-143.
|
|
[30]Taltavull TC, Chahri N, Verdura B, et al.Successful treat-ment with tenofovir in a child C cirrhotic patient with lamivu-dine-resistant hepatitis B virus awaiting liver transplanta-tion.Post-transplant results[J].Transpl Int, 2005, 18 (1) :879-883.
|
|
[31]Garg H, Sarin SK, Kumar M, et al.Tenofovir improves theoutcome in patients with spontaneous reactivation of hepati-tis B presenting as acute-on-chronic liver failure[J].Hep-atology, 2011, 53 (3) :774-780. (本文编辑:刘晓红
|
DownLoad: